Acadia Pharmaceuticals Inc. Earnings

Acadia Pharmaceuticals Inc.’s revenue jumped 9.39% since last year same period to $283.99Mn in the Q4 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 1.92% jump in its revenue since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit jumped 90.32% since last year same period to $273.57Mn in the Q4 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 281.13% jump in its net profits since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit margin jumped 73.98% since last year same period to 96.33% in the Q4 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 273.94% jump in its net profit margins since last 3-months.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.05 - a -62.56% fall from last quarter’s estimates.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.05.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Acadia Pharmaceuticals Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.